New Delhi, April 14 -- The Production Linked Incentive (PLI) scheme, launched in 2020, represents a transformative approach to bolstering domestic manufacturing across three key pharmaceutical segments.

The scheme for pharmaceuticals, approved in February 2021 with a financial outlay of Rs 15,000 crore, provides incentives to 55 selected applicants for manufacturing high-value products including biopharmaceuticals, complex generics, and anti-cancer drugs through fiscal year 2027-28.

A parallel PLI initiative for Key Starting Materials, Drug Intermediates, and Active Pharmaceutical Ingredients was established in March 2020 with a Rs 6,940 crore financial commitment through fiscal year 2029-30.

This program aims to reduce import dependen...